<DOC>
	<DOCNO>NCT00050960</DOCNO>
	<brief_summary>This study evaluate use Targretin capsule ( bexarotene ) combination standard chemotherapy treatment metastatic Non-Small Cell Lung Cancer ( NSCLC ) patient yet receive chemotherapy lung cancer .</brief_summary>
	<brief_title>Evaluation Efficacy , Safety Tolerability Targretin Capsules Patients With Advanced Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This study evaluate use Targretin capsule ( bexarotene ) combination Carboplatin Paclitaxel treatment metastatic non-small cell lung cancer patient yet receive chemotherapy lung cancer . Every patient receive platinum-containing chemotherapy every three week least four chemotherapy cycle ( approximately four month ) . Half patient randomly assign receive Targretin capsule daily addition chemotherapy . The half randomized receive standard platinum-containing chemotherapy without Targretin capsule .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must : Pathologic ( histologic cytologic ) confirmation NSCLC Stage IIIB malignant pleural effusion Stage IV disease At least one measurable evaluable NSCLC lesion previously irradiate unless radiation therapy three week prior entry study lesion show progressed subsequent radiation therapy ECOG performance status 0 1 Adequate organ system function Fasting serum triglyceride within ageadjusted normal range ( normalized appropriate intervention antilipid therapy prior initiation Targretin capsule therapy ) . Patients must able complete least four cycle combination chemotherapy ( i.e. , approximately four month ) Patients must : Brain metastasis Prior chemotherapy NSCLC Prior platinumbased chemotherapy indication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Targretin</keyword>
	<keyword>Retinoid</keyword>
	<keyword>Bexarotene</keyword>
</DOC>